Form 3 ELMS STEVE For: Mar 29 Filed by: Zosano Pharma Corp
FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/29/2018 |
3. Issuer Name
and
Ticker or Trading Symbol
Zosano Pharma Corp [ ZSAN ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check
Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock, par value of $0.0001 | 1,600,000 |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
See Signatures on Exhibit 99.1 | 04/09/2018 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
EXHIBIT 99.1
FORM 3 JOINT FILER INFORMATION
Names of Joint Filers:
Aisling Capital IV, LP
Steve Elms
Andrew N. Schiff, M.D.
Address of Joint Filers:
c/o Aisling Capital Management LP
888 Seventh Avenue, 12th Floor
New York, NY 10106
Designated Filer: Aisling Capital IV, LP
Issuer and Ticker Symbol: Zosano Pharma Corporation [ZSAN]
Date of Event: March 29, 2018
Signatures of Joint Filers:
AISLING CAPITAL IV, LP
|
|
By:
|
Aisling Capital Partners IV, LP
|
General Partner
|
|
By:
|
Aisling Capital Partners IV LLC
|
General Partner
|
|
By:
|
/s/ Andrew Schiff
|
Name: Andrew Schiff
|
|
Title: Managing Member
|
|
/s/ Steve Elms
|
Steve Elms
|
/s/ Andrew Schiff
|
Andrew Schiff
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RedSense Announces Revolutionary Public Sector Safety Shield Solution
- LNC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Lincoln National Corporation Investors with Substantial Losses Have Opportunity to Lead the Lincoln National Class Action Lawsuit
- Osceola, Iowa’s Housing Boom: Working to Meet All Levels of Housing Needs
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!